Literature DB >> 7035596

Rise in plasma concentration of aldosterone during long-term angiotensin II suppression.

J Staessen, P Lijnen, R Fagard, L J Verschueren, A Amery.   

Abstract

The plasma concentration of aldosterone was followed in seven hypertensive patients before and during long-term angiotensin II suppression with the orally active angiotensin-I-converting-enzyme inhibitor, captopril. The plasma concentration of aldosterone decreased initially from 74 to 21 pg/ml (P less than 0.05) after 1 month of administration of captopril. Thereafter the plasma concentration of aldosterone began to rise and after 1 year reached a level of 165 pg/ml. During long-term captopril therapy the plasma renin activity remained increased and the plasma angiotensin II concentration suppressed. The mechanism responsible for the late rise of the plasma concentration of aldosterone during long-term angiotensin II suppression with captopril remains to be elucidated. A sizeable and lasting hypotensive effect was observed in all patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7035596     DOI: 10.1677/joe.0.0910457

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  58 in total

Review 1.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

2.  Adding low-dose spironolactone to multidrug regimens for resistant hypertension.

Authors:  Kathleen H Berecek; Amal Farag; Gul Bahtiyar; Jeffery Rothman; Sammy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 3.  Chronic kidney disease and albuminuria in arterial hypertension.

Authors:  Giovanna Leoncini; Francesca Viazzi; Roberto Pontremoli
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

Review 4.  Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

5.  Imidapril: will fewer adverse events translate into better long-term outcomes?

Authors:  Tom Richart; Jan A Staessen; Willem H Birkenhäger
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure.

Authors:  Kurt R Daniel; Gretchen Wells; Kathryn Stewart; Brian Moore; Dalane W Kitzman
Journal:  Congest Heart Fail       Date:  2009 Mar-Apr

Review 7.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 8.  Appropriate drug therapy for improving outcomes in diabetic nephropathy.

Authors:  Robert D Toto
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 9.  Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience.

Authors:  Ward A Heggermont; Marc Goethals; Riet Dierckx; Sofie Verstreken; Jozef Bartunek; Marc Vanderheyden
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 10.  Aldosterone receptor antagonists: biology and novel therapeutical applications.

Authors:  P Magni; M Motta
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.